Valeant Pharmaceuticals International
(NYSE: VRX)
86.41
+0.55
+0.64%
+0.55
+0.64%
MORE ON VRX
COMPANY INFORMATION
| Exchange: | New York Stock Exchange |
| Stock: | Valeant Pharmaceuticals International Inc |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Employees: | 400 |
DESCRIPTION
| Valeant Pharmaceuticals International Inc was formerly known as Biovail Corporation. It is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant is focused on the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Europe and Australia. The Company’s specialty pharmaceutical and over-the-counter products are marketed under brand names and are sold in the United States, Canada, Australia and New Zealand, where its focus most of its efforts on products in the dermatology and neurology therapeutic classes. The Company also has branded generic, branded, and OTC operations in Europe, Latin America, South East Asia and South Africa. The Company has five business segments comprising of U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics — Europe and Branded Generics — Latin America. The Company’s principal Neurology and Other products are: Wellbutrin XL® and Xenazine®. Its principal dermatology products are: Zovirax® Ointment, Xerese®, Elidel®, Acanya® gel, Atralin® gel. Its principal OTC products are: CeraVe®, Kinerase®. The Company’s principal products sold in the Canadian market are: Cesamet®, Tiazac® XC, Wellbutrin® XL. Its principal OTC products in Canada are: Cold-FX® and in Australian market are: Duromine®/Metermine®, Cough and Cold OTC product, Difflam®, Duro-Tuss® and Rikodeine®. The Branded Generics — Europe segment generates revenues in more than 20 countries in Central and Eastern Europe from branded generic pharmaceutical products, OTC products and from agency/in-licensing arrangements with other research-based pharmaceutical companies. Products are sold primarily in Poland, Serbia, Hungary, Croatia and Russia. The Company’s combined European branded generics business now covers a broad range of treatments including antibiotics, treatments for cardiovascular and neurological diseases, antifungal medications and diabetic therapies among many others. The Branded Generics — Latin America segment generates revenues from branded generic pharmaceutical products and OTC products in Mexico and Brazil and exports out of Mexico to other Latin American markets. The Company’s portfolio covers a broad range of therapeutic classes including vitamin deficiency, antibacterials and dermatology. Its main product in this market is Bedoyecta®, a brand of vitamin B complex (B1, B6 and B12 vitamins) products. The Company’s competitors include specialty and large pharmaceutical companies, biotechnology companies, OTC companies, academic and other research and development institutions and generic manufacturers, both in the U.S., Canada and abroad. The Company is subject to laws and regulations concerning the environment, safety matters, regulation of chemicals and product safety in the countries where it manufactures and sells products or otherwise operate business. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] Equities ended on their lows with the S&P 500 down 1.4%. The S&P entered today's session with a week-to-date gain of 1.5% as investors expected reassuring words from today's Federal Open Market Committee Statement. Stocks traded with s
...
More
MORE MARKET NEWS
Sponsored by: